Barinthus Biotherapeutics Plc ADR(BRNS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.02 | Insider Own | 3.48% | Shs Outstand | 40.9M | Perf Week | - |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | -16.56% | Insider Trans | - | Shs Float | 39.4M | Perf Month | 22.88% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | -0.26 | Inst Own | 19.05% | Short Float | 0.03% | Perf Quarter | 11.77% |
| Income | -0.04B | P/S | - | EPS this Y | 34.96% | Inst Trans | - | Short Ratio | 0.23 | Perf Half Y | 17.48% |
| Sales | 0.00B | P/B | 0.53 | EPS next 5Y | 11.16% | ROA | -39.41% | Short Interest | 0.01M | Perf YTD | 5.71% |
| Book/sh | 1.4 | P/C | 0.51 | EPS past 3/5Y | - | ROE | -52.27% | 52W High | -59.56% ($1.83) | Perf Year | -39.09% |
| Cash/sh | 1.46 | P/FCF | - | Sales past 3/5Y | - | ROIC | -63.48% | 52W Low | 44.55% ($0.51) | Perf 3Y | -59.34% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 41.21% | Gross Margin | - | Volatility(W/M) | 11.76% 8.68% | Perf 5Y | -95.08% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.54 | EPS Q/Q | 51.05% | Profit Margin | - | RSI (14) | 60.26 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.54 | Sales Q/Q | - | SMA20 | 11.55% ($0.66) | Beta | -0.34 | Target Price | $6 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/8/6 | SMA50 | 17.58% ($0.63) | Rel Volume | 0 | Prev Close | $0.74 |
| Employees | 14 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | - | SMA200 | 12.43% ($0.66) | Avg Volume(3M) | 0.06M | Price | $0.74 |
| IPO | 2021/4/30 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🛡️ Barinthus Biotherapeutics (formerly Vaccitech) is a UK-based biotech that develops therapeutics for autoimmune and inflammatory diseases based on its proprietary <strong>SNAP-TI immune tolerance platform</strong>. Its lead candidate is <strong>VTP-1000</strong>, a treatment for celiac disease, and it also holds viral vector–based assets including VTP-300 for chronic hepatitis B and VTP-850 for prostate cancer. It is a nano-cap biotech listed on Nasdaq () as an ADR.
Over the past 1 year, on the lower side
60% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
BRNS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +35.0% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.1%.
Tap to view numbers
It ranks #445 of 598 in the industry
Based on market cap of $30M.
BRNS#445 Barinthus Biotherapeutics Plc ADR $30M PER - 
FLNA#445 Filana Therapeutics Inc $30M PER - 
EYPT#446 EyePoint Inc $30M PER - 
ALGS#447 Aligos Therapeutics Inc $30M PER - 
AARD#448 Aardvark Therapeutics Inc $30M PER - 
FAQ
What kind of company is BRNS?
BRNS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BRNS?
The market cap of BRNS is approximately $30M, ranking 5,152 within its sector.
What is the 52-week high and low for BRNS?
BRNS has recorded a 52-week high of $1.83 and a low of $0.51.
